ORNBV.HE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 11:29):

Stats
Today's Volume	894 998
Average Volume	253 285
Market Cap	5.29B
EPS	€0.310 ( 2024-04-25 )
Next earnings date	( €0.310 ) 2024-08-07
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	24.34
ATR14	€0.0160 (0.04%)

Volume Correlation

Long: 0.20 (neutral)

Short: 0.59 (weak)

Signal:(26.25) Neutral

Orion Oyj Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Orion Oyj Correlation - Currency/Commodity

0.36
( neutral )

0.15
( neutral )

0.00
( neutral )

-0.43
( neutral )

0.11
( neutral )

-0.29
( neutral )

Orion Oyj Financials

Annual	2023
Revenue:	€1.19B
Gross Profit:	€657.80M (55.29 %)
EPS:	€1.550

FY	2023
Revenue:	€1.19B
Gross Profit:	€657.80M (55.29 %)
EPS:	€1.550

FY	2022
Revenue:	€1.34B
Gross Profit:	€849.00M (63.33 %)
EPS:	€2.49

FY	2021
Revenue:	€1.04B
Gross Profit:	€593.50M (57.01 %)
EPS:	€1.379

Financial Reports:

No articles found.

Orion Oyj Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.